Teva Pharmaceutical Industries Ltd (ADR) (TEVA) was Reiterated by Mizuho to “Buy” while Lowering the Price Target of the company shares to $ 64 from a previous price target of $70 . Mizuho advised their investors in a research report released on Aug 25, 2016.
Many Wall Street Analysts have commented on Teva Pharmaceutical Industries Ltd (ADR). Shares were Reiterated by Mizuho on Aug 8, 2016 to “Buy” and Lowered the Price Target to $ 70 from a previous price target of $75 .Teva Pharmaceutical Industries Ltd (ADR) was Upgraded by HSBC Securities to ” Buy” on Jul 18, 2016. Teva Pharmaceutical Industries Ltd (ADR) was Downgraded by Goldman to ” Neutral” on Jul 15, 2016.
On the company’s financial health, Teva Pharmaceutical Industries Ltd (ADR) reported $1.25 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.21. The company had revenue of $5038.00 million for the quarter, compared to analysts expectations of $4880.16 million. The company’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.43 EPS.
Teva Pharmaceutical Industries Ltd (ADR) closed down -0.28 points or -0.52% at $53.2 with 34,37,298 shares getting traded on Tuesday. Post opening the session at $53.45, the shares hit an intraday low of $53.11 and an intraday high of $53.835 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company’s generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines which manufactures and sells generic pharmaceutical products in several dosage forms including tablets capsules injectables inhalants liquids ointments and creams and Specialty medicines which delivers solutions to patients and providers via medicines devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda Trisenox Granix Synribo Lonquex Tevagrastim/Ratiograstim Myocet Trisenox and Eporatio. Its women’s health portfolio includes ParaGard Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.